Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin

Vox Sanguinis

Volumn 83, Issue 2, 2002, Pages 137-145

  Reichl, H E ^a   Foster, Peter R ^b   Welch, A G ^b   Li, Q ^b   MacGregor, I R ^b   Somerville, R A ^c   Fernie, K ^c   Steele, P J ^c   Taylor , D M ^c  

^a Haemosan Life Science Services GmbH   (Austria)

^b SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Creutzfeldt Jakob disease; Ethanol fractionation; Intravenous immunoglobulin

Indexed keywords

ALCOHOL; GLASS FIBER; IMMUNOGLOBULIN; PRION PROTEIN;

ALGORITHM; ANIMAL EXPERIMENT; ARTICLE; BIOFILTRATION; BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN TISSUE; CELL FRACTIONATION; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG MANUFACTURE; GOOD LABORATORY PRACTICE; INCUBATION TIME; INFECTION PREVENTION; INFECTION RISK; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS MODEL; RISK ASSESSMENT; THEORETICAL MODEL; TIME SERIES ANALYSIS;

ANIMALS; BRAIN; CATTLE; CHEMICAL FRACTIONATION; CHEMISTRY, PHARMACEUTICAL; CONSUMER PRODUCT SAFETY; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; FILTRATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICROSOMES; PRECIPITATION;

EID: 0012954118     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2002.00211.x     Document Type: Article

References (32)

1. Wells GAH, Scott AC, Johnson CT, Gunning RF, Hancock RD, Jeffrey M, Bradley R: A novel progressive spongiform encephalopathy in cattle. VetRec 1987; 121:419-420
2. Braakman JL: BSE in Europe, 7 December 2001. www.ourworld.cs.com/jlbraakman/BSE.htm
3. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347:921-925
4. Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J, Doey LJ, Lantos P: The same prion strain causes vCJD and BSE. Nature 1997; 389:448-450
5. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ: Transmissions to mice indicate that 'new' variant' CJD is caused by the BSE agent. Nature 1997; 389:498-501
6. Brown P: Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. BMJ 2001; 322:841-844
7. Department of Health: Monthly Creutzfeldt-Jakob Disease Statistics. London, UK Department of Health, 2002. www.doh.gov.uk/cjd/stats/apr02.htm
8. Institute de Veille Sanitaire: Nombre de Cas de Maladie Creutzfeldt-Jakob. Paris, Saint-Maurice Institute de Veille Sanitaire, 2002. www.invs.sante.fr/publications/mcj/donnees_mcj.html
9. Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, d'Aignaux JH, Cervenáková L, Fradkin J, Schonberger LB, Collins SJ: latrogenic Creutzfeldt-Jakob disease at the millenium. Neurology 2000; 55:1075-1081
10. Vamvakas EC: Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives. J Clin Apheresis 1999; 14:135-143
11. Hill AF, Zeidler M, Ironside J, Collinge J: Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349:99-100
12. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, Frosh A, Tolley N, Bell JE, Spencer M, King A, Al-Sarraj S, Ironside JW, Lantos PL, Collinge J: Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353:183-189
13. Foster PR: Prions and blood products. Ann Med 2000; 32:501-513
14. Farrugia A: Risk of variant Creutzfeldt-Jakob disease from factor concentrates: current perspectives. Haemophilia 2002; 8:230-235
15. Det Norske Veritas: Assessment of the Risk of Exposure to vCJD Infectivity in Blood and Blood Products. Final report for the Spongiform Encephalopathy Advisory Committee and the Department of Health. London, Det Norske Veritas, 1999. www.dnv.com
16. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN: The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38:810-816
17. Brown P, Cervenáková L, McShane LM, Barber P, Rubenstein R, Drohan WN: Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39:1169-1178
18. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC: Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78:86-95
19. Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JLC, Gilligan KJ, Rubenstein R, Fournel M, Petteway SR: Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000; 84:77-89
20. Lee DC, Stenland CJ, Miller JLC, Cai K, Fort EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR: A direct relationship between partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41:449-455
21. Millson GC, Hunter GD, Kimerlin RH: An experimental examination of the scrapie agent in cell membrane mixtures. II. The association of scrapie activity with membrane fractions. J Comp Pathol 1971; 81:255-265
22. Dickinson AG, Meikle VM, Fraser H: Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J Comp Pathol 1968; 78:293-299
23. Bruce ME: Strain typing studies of scrapie and BSE; in Baker H, Ridley RM (eds): Methods in Molecular Medicine: Prion Diseases. Totowa, New Jersey, Humana Press 1996:223-236
24. Dougherty R: Animal virus titration techniques; in Harris R (ed.): Techniques in Experimental Virology. London, Academic Press, 1964:169-223
25. Farquhar CF, Dornan J, Moore RC, Somerville RA, Tunstal AM, Hope J: Protease-resistant PrP deposition in brain and non-central nervous system tissue of a murine model of bovine spongiform encephalopathy. J Gen Virol 1996; 77:1941-1946
26. Stenland CJ, Miller JLC, Cai K, Evans-Storms R, Ford EK, Fournel M, Gilligan KJ, Hartwell RC, Petteway SR, Terry JC, Rubenstein R, Lee DC: Tracking partitioning of the pathogenic form of the human prion protein during plasma fractionation using a sensitive Western blot assay. Thromb Haemost 2001; 86: Abstract number P2606
27. Scott MR, Will R, Ironside J, Nguyen HO, Tremblay P, DeArmond SJ, Prusiner SB: Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA 1999; 96:15137-15142
28. Lasmezas CI, Fournier JG, Nouvel V, Boe H, Marce D, Lamoury F, Kopp N, Hauw JJ, Ironside J, Bruce M, Dormont D, Deslys JP: Adaption of bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health. Proc Natl Acad Sci USA 2001; 98:4142-4147
29. Bruce ME, Chree A, McConnell I, Foster J, Pearson G, Fraser H: Transmission of bovine spongiform encephalopathy and scrapie to mice strain variation and the species barrier. Phil Trans Roy Soc Lond B 1994; 343:405-411
30. Taylor DM, Fernie K, Reichl HE, Somerville RA: Infectivity in the blood of mice with a BSE-derived agent. J Hosp Infect 2000; 46:78-79
31. Kimberlin RH, Walker CA: Pathogenesis of scrapie (strain 263K) in hamsters infected intracerebrally, intraperitoneally or intraocularly. J Gen Virol 1986; 67:255-263
32. Morgenthaler JJ: Partitioning of TSE agent(s) during ethanol fractionation of human plasma; in Brown MA, Diomede K (eds): Proceedings of Cambridge Healthtech Institute Conference, 'TSE Issues', Lisbon, November, 1998. Newton Upper Falls, Maryland, Cambridge Healthtech Institute, 1998